This webinar recording is hosted by Katya Kowalski, Head of Operations at Volteface. The expert panel includes: Dr George Eralil, Aneeta Prem – CEO of Trigeminal Neuralgia Association, Hannah Simon – COO of Script Assist and Teri Miller a TN patient.

As medical cannabis prescriptions in the UK continue to rise, more individuals diagnosed with Trigeminal Neuralgia are seeking information about whether medical cannabis could provide relief for their condition. The growing body of research on medical cannabis suggests its potential efficacy in managing various conditions, including Trigeminal Neuralgia. Studies indicate that cannabinoids, the active compounds in cannabis, possess analgesic and anti-inflammatory properties that may alleviate neuropathic pain associated with Trigeminal Neuralgia. For those who have not responded well to traditional pharmacological interventions, medical cannabis represents a promising alternative.

Despite the increasing availability of medical cannabis prescriptions since legalisation, many individuals diagnosed with Trigeminal Neuralgia in the UK remain unaware of its potential therapeutic benefits and legal status for treating their condition. This knowledge gap poses a barrier to accessing a potentially beneficial treatment option.

This recorded webinar provides information about the use of medical cannabis for Trigeminal Neuralgia, facilitating access where appropriate. The webinar addresses:

– The increasing trend of medical cannabis prescriptions in the UK
– Evidence supporting the use of medical cannabis for Trigeminal Neuralgia, including recent research findings
– Clinical perspectives and experiences in prescribing medical cannabis for Trigeminal Neuralgia
– Patient experiences with cannabis-based medicines for treating Trigeminal Neuralgia
– Access routes for patients and the prescribing process in the UK

source